• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Dysmenorrhea - Pipeline Review, H1 2012 Product Image

Dysmenorrhea - Pipeline Review, H1 2012

  • Published: February 2012
  • 59 pages
  • Global Markets Direct

Dysmenorrhea – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, H1 2012', provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides information on the therapeutic development for Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysmenorrhea. 'Dysmenorrhea - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dysmenorrhea.
- A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dysmenorrhea Overview
Therapeutics Development
An Overview of Pipeline Products for Dysmenorrhea
Dysmenorrhea Therapeutics under Development by Companies
Dysmenorrhea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Dysmenorrhea Therapeutics – Products under Development by Companies
Dysmenorrhea Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Dysmenorrhea Therapeutics Development
Columbia Laboratories Inc.
Plethora Solutions Holdings plc
China Aoxing Pharmaceutical Co., Inc
PDC Biotech GmbH
Nobelpharma Co., Ltd.
Vantia Therapeutics
Jiangsu Kanion Pharmaceutical Co., Ltd.
Dysmenorrhea – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Peptidometics - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC41 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDC31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD508 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VA111913 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viagra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gestodene + Ethinyl Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenellin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitagnus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kanion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TJSL Capsule - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPC-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mefenamic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Colpermin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zinc - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omega-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dysmenorrhea Therapeutics – Discontinued Products
Dysmenorrhea Therapeutics - Dormant Products
Dysmenorrhea – Product Development Milestones
Featured News & Press Releases
Jul 19, 2010: Aoxing Pharma Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules
Jul 19, 2010: Aoxing Pharmaceutical Company Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules
Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913
Jan 05, 2010: China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007
Nov 09, 2007: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007.
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007
Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dysmenorrhea, H1 2012
Products under Development for Dysmenorrhea – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Columbia Laboratories Inc., H1 2012
Plethora Solutions Holdings plc, H1 2012
China Aoxing Pharmaceutical Co., Inc, H1 2012
PDC Biotech GmbH, H1 2012
Nobelpharma Co., Ltd., H1 2012
Vantia Therapeutics, H1 2012
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dysmenorrhea Therapeutics – Discontinued Products
Dysmenorrhea Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Dysmenorrhea, H1 2012
Products under Development for Dysmenorrhea – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos